MELLARIL
LOE ApproachingNDAORALCONCENTRATEPriority Review
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1w ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MELLARIL is an oral concentrate small-molecule antipsychotic approved in 1962 by Novartis. The drug's mechanism of action and specific indications are not publicly detailed in available data, though it represents a legacy neuroleptic from the first generation of antipsychotics. It is administered orally as a concentrated formulation.
LOE Approaching
As LOE approaches, the MELLARIL brand team likely operates with minimal headcount focused on maintenance, supply chain, and regulatory compliance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MELLARIL offers limited career growth potential, with zero linked job openings and an approaching loss of exclusivity. Roles are maintenance-focused, emphasizing operational excellence, cost control, and compliance rather than innovation or market expansion.
Brand ManagerRegulatory Affairs Specialist
Worked on MELLARIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.